The post Neuronaute® Plus, BIOSerenity’s comprehensive simplified EEG device, has received FDA clearance appeared first on BioSerenity.
]]>Paris, FRANCE, Boston, MA, USA
BIOSerenity, a leader in EEG Technology announces the FDA Clearance of Neuronaute® Plus. A device opening up new possibilities for EEG Recordings.
Neuronaute® Plus is a small portable medical device collecting data that loads into the cloud to enable any specialist in Europe, in Canada and in the US to analyze EEG recordings. It is so easy to use, that very little training is needed. Combined with the ease of use and simplicity of the Icecap®, an innovative EEG electrode net, the Neuronaute® Plus is helping healthcare professionals perform EEG recordings and monitoring in a cost-effective way.
According to Dr. Bruce Lavin, Chief Medical Officer: “BIOSerenity’s Neuronaute® solution is addressing a particularly strong medical need by allowing convenient diagnoses of epilepsy and other significant brain disorders with minimal technologic support . We are excited to offer an important solution that will benefit patients and assist Hospitals and Neurologists in providing greater EEG accessibility for over 3.5 million people living with Epilepsy in the US”.
Vincent Marcel, CEO added: “Getting the right technology to diagnose and training staff can be real challenges. We are very proud to bring enhanced innovation to make EEG more accessible for doctors and patients and to allow doctors to go even further to patients’ life. With the strong support of Jolt Capital, we look forward bringring worldwide more personalized, preventive and costeffective medicine for neurological in the US and other geographies. »
The Neuronaute® Plus is the size of a smartphone, communicates wirelessly, allows for a seamless battery change for extended recordings without interruptions, allows for live monitoring with or without video and is compatible with both traditonal EEG cup electrodes or the Icecap®, a fast and convenient disposable electrode system that reduces time of installation by up to 50%*.
Launched in Europe in the summer, the Neuronaute® Plus has already started to open up new opportunities to address epilepsy diagnoses. Its convenience has allowed doctors to explore new use cases such as using the Neuronaute® in remote areas, in the Operating Room, in the Intensive Care Unit or for long term home monitoring but also in Pediatric Monitoring in each geography.
Following the FDA Clearance, the Neuronaute® Plus will be launched in the US Market at the AES Conference in Orlando, Florida on December 1st, 2023 and will be made available to hospitals and doctors all over the country. Come see us at our AES Booth #223.
*Based on Internal study
About BIOSerenity
Founded in 2014 and headquartered in Paris, France, and Boston, MA, USA, BIOSerenity is
an innovative Medical Technology company focused on Healthcare as a Service, IoMT, A.I.
and Real World Evidence in Neurology, Sleep, Cardiology. The company is the recipient of
many awards in Business and Medicine. The company has deployed solutions such as the
Neuronaute®, a long term ambulatory EEG solution and LR, software solutions to help
doctors provide care to patients as efficiently as possible, anytime, anywhere.
For more information: https://bioserenity.com
BIOSerenity
[email protected]
The post Neuronaute® Plus, BIOSerenity’s comprehensive simplified EEG device, has received FDA clearance appeared first on BioSerenity.
]]>The post Jolt Capital invests in BIOSerenity, a leader in neurological diagnostics and sleep disorders appeared first on BioSerenity.
]]>Paris, 13 November 2023
Jolt Capital, an independent private equity firm specializing in growth investment in European deeptech companies, is investing €24m in BIOSerenity, a specialist in connected medical devices and innovative medical services in electrophysiology.
Thanks to the relevance of its research, the services it has developed and its experts, BIOSerenity has been able to differentiate itself and become a genuine benchmark in its market. This key investment for Jolt Capital is in line with its strategy of acquiring European companies with very high potential.
Jean Schmitt, Managing Partner and Chairman of Jolt Capital, comments: “Healthcare is one of the strategic sectors that needs to benefit from an acceleration in funding if we are to see French medical and industrial leadership emerge. This is why we are delighted to invest in BIOSerenity, which has created the best medical devices and AI software on the market for electroencephalography. BIOSerenity is a perfect example of Jolt Capital’s investment thesis. When a company has a proprietary base of market-proven, cuttingedge technologies, its ability to attract significant financing to support its development remains intact”.
Founded in 2014, BIOSerenity has designed an unrivalled range of medical devices and software for electroencephalography. The company has also extended the scope of its innovative solutions to other fields, including sleep disorders. Today, with more than 300 partners and 150,000 patients treated each year, BIOSerenity has become a leader in neurological diagnostics and sleep disorders.
“As we enter the next phase of our development, we are delighted to benefit from Jolt Capital’s recapitalization following the recent growth crisis” commented Pierre-Yves Frouin, Founder, and Samir Medjebar, General Manager Services in France. “In less than 10 years, our technology has helped more than a million patients and we have spearheaded innovation in the fields of ambulatory neurology, sleep and medical AI. This next step will allow us to bring our technology to more patients and continue to innovate.”
Jolt Capital’s investment of €24m will enable the company to accelerate the international development of its activities by building on its two main markets, France and the United States, and focusing on Europe. The funding will also be used to deploy even more powerful artificial intelligence to help doctors with their diagnoses. Finally, the company’s management team will be strengthened to drive BIOSerenity’s development.
Vincent Marcel has been appointed CEO of the company: “I am impressed by the unique combination of disruptive technologies that BIOSerenity has developed in the field of neurology and innovative patient care services. I look forward to leading the next stage of development, leaning on my experience in healthcare services and the strong commitment of Jolt Capital. Together with the BIOSerenity teams, we will accelerate in Europe and the United States to bring personalized, preventive and cost-effective
medicine for neurological and sleep disorders.»
About Jolt Capital (https://www.jolt-capital.com )
Jolt Capital is an independent private equity firm specialized in growth investing in
deeptech companies, with a mission to build future European leaders with a global focus.
Since 2011, Jolt Capital invests in European B2B companies with revenues between €10M
and €50M. Jolt Capita’s team is composed solely of experienced investors and managers of
high-tech companies. Its proprietary AI platform, Jolt.Ninja, enables enriched sourcing,
accelerated due diligence and automatic detection of investment or acquisition targets.
Jolt Capital is located in Paris, Lausanne, Copenhagen, and Milan.
General media contact (Steele&Holt)
[email protected]
+33 6 33 73 85 16
To know more about Jolt Capital:
Philippe Perez (Head of Marketing)
[email protected]
+33 6 23 82 67 19
The post Jolt Capital invests in BIOSerenity, a leader in neurological diagnostics and sleep disorders appeared first on BioSerenity.
]]>The post BIOSerenity announces 1 million patients cared for appeared first on BioSerenity.
]]>BIOSerenity, designer of innovative electrophysiology medical solutions, has reached a significant milestone in patient monitoring and diagnosis.
BIOSerenity’s mission
The birth of BIOSerenity is directly linked to the difficulties encountered in the care of epilepsy patients. Patients generally face major obstacles when it comes to obtaining an accurate diagnosis of their disease. It is crucial to understand that the diagnosis of epilepsy relies on an electrophysiological examination of the brain, known as an EEG (Electroencephalography). However, access to the EEG is often considered difficult, due to the complexity of both performing and interpreting the examination. This situation generates diagnostic errancy for patients, delaying appropriate medical management and additional costs for the healthcare system.
In 2014, in response to this problem, BIOSerenity is committed to developing innovative solutions to democratize access to EEG. This optimization of electrophysiological diagnosis was then extended, notably in the field of Sleep Disorders.
Since then, BIOSerenity’s teams have worked relentlessly to make electrophysiology accessible to all, thereby combating therapeutic erraticism, and to provide healthcare professionals with IT tools for better management, whether via LR, a SaaS platform for managing sleep clinics and ventilatory polygraphs, or via BIOSerenity A.I., an Artificial Intelligence diagnostic aid for Neurology and Sleep Disorders.
Since its creation in 2014, within the Institut du Cerveau et de la Moelle Épinière (ICM) at the Pitié-Salpêtrière Hospital (AP-HP, Paris), the company has established itself as a benchmark in the performance and remote interpretation of electrophysiological examinations.Thanks to its recognized expertise, BIOSerenity’s teams of engineers, researchers and healthcare professionals put their know-how at the service of today’s medicine, enabling the company to collaborate with over 300 hospitals and 10,000 healthcare professionals in France and the United States.
“1 million patients have been diagnosed and are now being monitored – it’s a great victory!We’re proud of this development and ready to contribute even more. DeepTech involving physical devices, precision electronics, a software platform and Artificial Intelligence is quite a challenge, and one that our teams have succeeded in meeting with the help of the medical community”, said Pierre- Yves Frouin, CEO of BIOSerenity.
About BIOSerenity is …
BIOSerenity opens up new perspectives in electrophysiological monitoring and diagnosis. Would you like to find out more?
More info : [email protected]
André Pitié
BIOSerenity
[email protected]
The post BIOSerenity announces 1 million patients cared for appeared first on BioSerenity.
]]>